Fulgent Genetics Inc. Common Stock (FLGT)
Stock · NASDAQ · Health Care
$19.85as of 10/16/2026
Price chart
Active signals
FLGT Signal Track Record
How signals performed across all stocks →What FLGT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 27 | +0.6% | 56% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 25 | +2.1% | 56% | July 31, 2026 |
| Bollinger Band Breakout | 21 | +0.6% | 52% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -8.3% | 45% | September 11, 2026 |
| Any 20-session window (baseline) | -1.7% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FLGT
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropatholo…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 1,315
- Website
- www.fulgentgenetics.com/
Fundamentals
- 1-day range
- $19.8$21.49
- Market cap
- $510.41M
- P/E (trailing)
- —
- P/E (forward)
- -14.39
- EPS (trailing)
- $-2.83
- Dividend yield
- —
- Beta
- 1.03
- Avg. volume
- 300.6K
How Fulgent Genetics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Feb 28, 2025 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Fulgent Genetics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FLGTFulgent Genetics Inc. Common Stock$19.81▼ 7.17%Market cap $510.41MP/E —$13.46$31.04
- TLSITriSalus Life Sciences Inc. Common Stock$3.63▼ 6.92%Market cap $299.10MP/E —$2.2$7.95
- BDSXBiodesix Inc. Common Stock$23.66▼ 4.25%Market cap $228.86MP/E —$5.26$31.97
- ACHAccendra Health Inc. Common Stock$0.24▼ 7.69%Market cap $223.62MP/E —$0.2615$5.6
- YDESYD Bio Limited Ordinary Shares$5.92▼ 12.17%Market cap $167.45MP/E —$1.7$22
- XGNExagen Inc. Common Stock$7.72▼ 9.81%Market cap $159.64MP/E —$2.59$12.23
- KEQUKewaunee Scientific Corporation Common Stock$32.93▲ 2.30%Market cap $108.73MP/E 11.26$32$46.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FLGT Fulgent Genetics Inc. Common Stock | $510.41M | — | $19.81 | ▼ 7.17% | $13.46$31.04 |
| TLSI TriSalus Life Sciences Inc. Common Stock | $299.10M | — | $3.63 | ▼ 6.92% | $2.2$7.95 |
| BDSX Biodesix Inc. Common Stock | $228.86M | — | $23.66 | ▼ 4.25% | $5.26$31.97 |
| ACH Accendra Health Inc. Common Stock | $223.62M | — | $0.24 | ▼ 7.69% | $0.2615$5.6 |
| YDES YD Bio Limited Ordinary Shares | $167.45M | — | $5.92 | ▼ 12.17% | $1.7$22 |
| XGN Exagen Inc. Common Stock | $159.64M | — | $7.72 | ▼ 9.81% | $2.59$12.23 |
| KEQU Kewaunee Scientific Corporation Common Stock | $108.73M | 11.26 | $32.93 | ▲ 2.30% | $32$46.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?Yahoo · 9/22/2026
Insider Activity
Insider Actions →- Xie Jian · September 2, 2026 · Sale2.1K @ $19.66
- Gao Hanlin · September 2, 2026 · Sale1.7K @ $19.66
- Ming Hsieh · September 1, 2026 · Tax Withholding4.4K @ $19.59
- Kim Paul · September 1, 2026 · Tax Withholding2.1K @ $19.59
- Xie Jian · August 27, 2026 · Sale1.2K @ $19.91
- Gao Hanlin · August 27, 2026 · Sale939 @ $19.91
- Ming Hsieh · August 26, 2026 · Tax Withholding2.9K @ $19.81
- Kim Paul · August 26, 2026 · Tax Withholding1.2K @ $19.81
- Xie Jian · July 26, 2026 · Tax Withholding4.4K @ $19.67
- Gao Hanlin · July 26, 2026 · Tax Withholding1.6K @ $19.67
- Kim Paul · July 26, 2026 · Tax Withholding2.7K @ $19.67
- Xie Jian · June 2, 2026 · Sale2.1K @ $17.89
- Gao Hanlin · June 2, 2026 · Sale1.7K @ $17.89
- Ming Hsieh · June 1, 2026 · Tax Withholding4.4K @ $18.09
- Kim Paul · June 1, 2026 · Tax Withholding2.1K @ $18.09
Institutional Ownership
March 31, 2026
- Total shares held
- 16.71M
- Total value held
- $244.66M
- Institutional holders
- 151
- Unknown2.77M
- Unknown1.29M
- Unknown1.23M
- Unknown880.1K
- Unknown671.7K
- Unknown610.3K
- Unknown584.2K
- Unknown563.4K
- Unknown529.4K
- Unknown486.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FLGT compared to PRPO in cancer diagnostics sector
A recent article compares Fulgent Genetics with PrecisionDx, evaluating which cancer diagnostics stock has more potential. This comparison highlights FLGT's position within the specialized diagnostics market. The stock is currently trading near the average analyst target price of $19.00, which sits within its 52-week range.
FLGT compared to PRPO in cancer diagnostics sector. A recent article compares Fulgent Genetics with PrecisionDx, evaluating which cancer diagnostics stock has more potential. This comparison highlights FLGT's position within the specialized diagnostics market. The stock is currently trading near the average analyst target price of $19.00, which sits within its 52-week range.